Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche’s MabThera is approved in Europe

Roche’s MabThera is approved in Europe

7th September 2009

Roche has revealed that its medicine for previously-treated chronic lymphocytic leukaemia has been approved for marketing in Europe.

MabThera is designed for use in those patients who have the most common form of the disease in adults – relapsed or refractory chronic lymphocytic leukaemia (CLL).

A recent REACH trial into the drug helped to support the approval and means that MabThera can now be prescribed by physicians alongside chemotherapy to patients who have been treated for the disease but have not responded sufficiently.

Professor Tadeusz Robak, from the Medical University of Lodz in Poland, said: “This will help ease the burden of the cancer and enable patients to enjoy the relative freedom that comes with this relief from symptoms.”

Last month, Roche announced that Avastin (bevacizumab), when administered alongside commonly-used chemotherapies, prolongs the worsening of untreated advanced breast cancer.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.